Literature DB >> 31430649

Genomic insights into MeCP2 function: A role for the maintenance of chromatin architecture.

Daniel R Connolly1, Zhaolan Zhou2.   

Abstract

Methyl-CpG binding protein 2 (MeCP2) plays fundamental roles in the nervous system, as both gain-of-function and loss-of-function of MECP2 are associated with severe neurological conditions. Understanding the molecular function of MeCP2 will not only provide insights into the pathogenesis of MeCP2-related disorders, but will also shed light on the epigenetic regulation of neuronal function. In the past few years, a number of studies have provided mechanistic evidence that MeCP2 recruits co-repressor complexes to particular sequences of methylated DNA. Additionally, innovative design and high-throughput sequencing technologies have provided opportunities to study the effects of MeCP2 on the neuronal transcriptome at an unprecedented level of detail, demonstrating that MeCP2 modulates gene expression in a context-specific manner. These findings have raised new questions and challenged current models of MeCP2 function. In this review, we describe several recent developments, highlight future challenges, and articulate a model by which MeCP2 functions as an organizer of chromatin architecture to modulate global gene expression in the nervous system.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31430649      PMCID: PMC6889049          DOI: 10.1016/j.conb.2019.07.002

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  58 in total

1.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.

Authors:  X Nan; H H Ng; C A Johnson; C D Laherty; B M Turner; R N Eisenman; A Bird
Journal:  Nature       Date:  1998-05-28       Impact factor: 49.962

2.  Cell-type-specific repression by methyl-CpG-binding protein 2 is biased toward long genes.

Authors:  Ken Sugino; Chris M Hempel; Benjamin W Okaty; Hannah A Arnson; Saori Kato; Vardhan S Dani; Sacha B Nelson
Journal:  J Neurosci       Date:  2014-09-17       Impact factor: 6.167

3.  Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome.

Authors:  Shin-ichi Horike; Shutao Cai; Masaru Miyano; Jan-Fang Cheng; Terumi Kohwi-Shigematsu
Journal:  Nat Genet       Date:  2004-12-19       Impact factor: 38.330

4.  Elevating expression of MeCP2 T158M rescues DNA binding and Rett syndrome-like phenotypes.

Authors:  Janine M Lamonica; Deborah Y Kwon; Darren Goffin; Polina Fenik; Brian S Johnson; Yue Cui; Hengyi Guo; Sigrid Veasey; Zhaolan Zhou
Journal:  J Clin Invest       Date:  2017-04-10       Impact factor: 14.808

5.  Phenotypic manifestations of MECP2 mutations in classical and atypical Rett syndrome.

Authors:  Carolyn Schanen; Elisa J F Houwink; Naghmeh Dorrani; Jane Lane; Ruth Everett; Alice Feng; Rita M Cantor; Alan Percy
Journal:  Am J Med Genet A       Date:  2004-04-15       Impact factor: 2.802

6.  Rett syndrome: revised diagnostic criteria and nomenclature.

Authors:  Jeffrey L Neul; Walter E Kaufmann; Daniel G Glaze; John Christodoulou; Angus J Clarke; Nadia Bahi-Buisson; Helen Leonard; Mark E S Bailey; N Carolyn Schanen; Michele Zappella; Alessandra Renieri; Peter Huppke; Alan K Percy
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

7.  Biotin tagging of MeCP2 in mice reveals contextual insights into the Rett syndrome transcriptome.

Authors:  Brian S Johnson; Ying-Tao Zhao; Maria Fasolino; Janine M Lamonica; Yoon Jung Kim; George Georgakilas; Kathleen H Wood; Daniel Bu; Yue Cui; Darren Goffin; Golnaz Vahedi; Tae Hoon Kim; Zhaolan Zhou
Journal:  Nat Med       Date:  2017-09-18       Impact factor: 53.440

8.  MeCP2, a key contributor to neurological disease, activates and represses transcription.

Authors:  Maria Chahrour; Sung Yun Jung; Chad Shaw; Xiaobo Zhou; Stephen T C Wong; Jun Qin; Huda Y Zoghbi
Journal:  Science       Date:  2008-05-30       Impact factor: 47.728

9.  Developmental delay in Rett syndrome: data from the natural history study.

Authors:  Jeffrey L Neul; Jane B Lane; Hye-Seung Lee; Suzanne Geerts; Judy O Barrish; Fran Annese; Lauren McNair Baggett; Katherine Barnes; Steven A Skinner; Kathleen J Motil; Daniel G Glaze; Walter E Kaufmann; Alan K Percy
Journal:  J Neurodev Disord       Date:  2014-07-22       Impact factor: 4.025

10.  A mutation-led search for novel functional domains in MeCP2.

Authors:  Jacky Guy; Beatrice Alexander-Howden; Laura FitzPatrick; Dina DeSousa; Martha V Koerner; Jim Selfridge; Adrian Bird
Journal:  Hum Mol Genet       Date:  2018-07-15       Impact factor: 6.150

View more
  11 in total

Review 1.  Epigenetics and Neuroinflammation Associated With Neurodevelopmental Disorders: A Microglial Perspective.

Authors:  Munekazu Komada; Yuhei Nishimura
Journal:  Front Cell Dev Biol       Date:  2022-05-12

Review 2.  Sex differences in Mecp2-mutant Rett syndrome model mice and the impact of cellular mosaicism in phenotype development.

Authors:  Mayara C Ribeiro; Jessica L MacDonald
Journal:  Brain Res       Date:  2020-01-02       Impact factor: 3.252

Review 3.  Intellectual and Developmental Disabilities Research Centers: A Multidisciplinary Approach to Understand the Pathogenesis of Methyl-CpG Binding Protein 2-related Disorders.

Authors:  Michela Fagiolini; Annarita Patrizi; Jocelyn LeBlanc; Lee-Way Jin; Izumi Maezawa; Sarah Sinnett; Steven J Gray; Sophie Molholm; John J Foxe; Michael V Johnston; Sakkubai Naidu; Mary Blue; Ahamed Hossain; Shilpa Kadam; Xinyu Zhao; Quiang Chang; Zhaolan Zhou; Huda Zoghbi
Journal:  Neuroscience       Date:  2020-04-29       Impact factor: 3.590

4.  Presymptomatic training mitigates functional deficits in a mouse model of Rett syndrome.

Authors:  Nathan P Achilly; Wei Wang; Huda Y Zoghbi
Journal:  Nature       Date:  2021-03-24       Impact factor: 69.504

Review 5.  MeCP2: The Genetic Driver of Rett Syndrome Epigenetics.

Authors:  Katrina V Good; John B Vincent; Juan Ausió
Journal:  Front Genet       Date:  2021-01-21       Impact factor: 4.599

Review 6.  Dental Pulp-Derived Mesenchymal Stem Cells for Modeling Genetic Disorders.

Authors:  Keiji Masuda; Xu Han; Hiroki Kato; Hiroshi Sato; Yu Zhang; Xiao Sun; Yuta Hirofuji; Haruyoshi Yamaza; Aya Yamada; Satoshi Fukumoto
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

Review 7.  The Molecular Functions of MeCP2 in Rett Syndrome Pathology.

Authors:  Osman Sharifi; Dag H Yasui
Journal:  Front Genet       Date:  2021-04-23       Impact factor: 4.599

Review 8.  Proteomic and transcriptional changes associated with MeCP2 dysfunction reveal nodes for therapeutic intervention in Rett syndrome.

Authors:  Ketan Marballi; Jessica L MacDonald
Journal:  Neurochem Int       Date:  2021-05-26       Impact factor: 4.297

Review 9.  MeCP2: A Critical Regulator of Chromatin in Neurodevelopment and Adult Brain Function.

Authors:  Kubra Gulmez Karaca; David V C Brito; Ana M M Oliveira
Journal:  Int J Mol Sci       Date:  2019-09-16       Impact factor: 5.923

10.  Protective role of mirtazapine in adult female Mecp2+/- mice and patients with Rett syndrome.

Authors:  Javier Flores Gutiérrez; Claudio De Felice; Giulia Natali; Silvia Leoncini; Cinzia Signorini; Joussef Hayek; Enrico Tongiorgi
Journal:  J Neurodev Disord       Date:  2020-09-28       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.